Business Context and Reporting Period
Company: BridgeBio Pharma, Inc. (BBIO)
Reporting Period: Fiscal Year Ended December 31, 2024
Business Overview: BridgeBio is a biopharmaceutical company focused on genetic diseases. The 2024 fiscal year marked a pivotal transition from a pre-commercial to a commercial-stage company following the FDA approval of Attruby (acoramidis) on November 22, 2024, for the treatment of transthyretin amyloid cardiomyopathy (ATTR-CM). The European Commission subsequently approved the product (branded as Beyonttra) on February 10, 2025. The company maintains a late-stage pipeline including low-dose infigratinib (achondroplasia), encaleret (ADH1), and BBP-418 (LGMD2I/R9).
Key Financial Metrics
| Metric | 2024 | 2023 |
|---|---|---|
| Revenue | $221.9 million | $9.3 million |
| Net Loss | $(543.3) million | $(653.3) million |
| Net Loss Attributable to Common Stockholders | $(535.8) million | $(643.2) million |
| Research & Development Expenses | $506.5 million | $455.7 million |
| Selling, General & Administrative Expenses | $288.9 million | $150.6 million |
| Cash and Cash Equivalents (Year End) | $681.1 million | $375.9 million |
| Total Debt (Principal) | $1.7 billion | $1.2 billion (Notes only) |
| Accumulated Deficit | $(3.1) billion | $(2.6) billion |
Note: Revenue in 2024 includes $207.7 million from upfront license fees (Bayer and Kyowa Kirin) and $2.9 million from initial Attruby product sales. Net loss improved primarily due to a $178.3 million gain on deconsolidation of subsidiaries (GondolaBio and BBOT).
Material Changes vs. Prior Period
- Revenue Surge: Revenue increased by $212.6 million (2,285%) driven by the recognition of upfront payments from the Bayer License Agreement ($135.0 million) and the Kyowa Kirin Agreement ($100.0 million), partially offset by the termination of the Navire-BMS agreement.
- Commercial Launch: Initiated U.S. commercial sales of Attruby in November 2024, generating $2.9 million in product revenue.
- Deconsolidation Gains: Recognized a $178.3 million gain from the deconsolidation of GondolaBio ($52.0 million) and BBOT ($126.3 million) following private equity financings that reduced BridgeBio's controlling interest.
- Expense Increases: SG&A expenses rose by $138.3 million due to commercialization readiness costs (sales force, marketing) and deal-related expenses. R&D expenses increased by $50.8 million due to higher personnel and external costs for key programs.
- Liquidity Position: Cash balances increased by $305.2 million year-over-year, bolstered by $500.0 million in proceeds from the Funding Agreement (triggered by FDA approval) and $450.0 million from a new Term Loan.
Guidance, Outlook, and Risks
Outlook and Milestones:
- Attruby/Beyonttra: Bayer is expected to launch Beyonttra in Europe in H1 2025. BridgeBio expects to receive a $75.0 million regulatory milestone payment from Bayer in April 2025 following EC approval.
- Pipeline: Phase 3 results are anticipated in H2 2025 for low-dose infigratinib (achondroplasia), encaleret (ADH1), and BBP-418 (LGMD2I/R9).
- Liquidity: Management expects cash and cash equivalents to fund operations for at least the next 12 months.
Key Risks and Contingencies:
- Commercialization Execution: Success depends on market acceptance, reimbursement rates, and the ability of the sales force to penetrate the ATTR-CM market against competitors (e.g., Pfizer's Vyndaqel).
- Debt Obligations: The company carries significant debt ($1.7 billion principal), including a $450 million Term Loan and a $500 million deferred royalty obligation (Funding Agreement) requiring 5% of global net sales of Attruby (capped at $950 million).
- Regulatory and Clinical: Risks include potential delays in Phase 3 trials, failure to meet endpoints, or adverse safety findings. The company relies entirely on third-party contract manufacturers (CMOs) for supply.
- Restructuring: Ongoing restructuring initiatives to reduce costs may not yield anticipated savings and could disrupt operations.
Investor Verification Checklist
- Attruby Sales Velocity: Verify early commercial uptake and reimbursement approval rates in the U.S. to assess the sustainability of product revenue beyond the initial launch.
- Debt Covenants: Review compliance with the Amended Financing Agreement, specifically the minimum unrestricted qualified cash balance requirement ($78.0 million as of Dec 31, 2024).
- Deferred Royalty Obligation: Monitor the effective interest rate and repayment schedule of the $500 million Funding Agreement, which is tied to future net sales performance.
- Phase 3 Data Readouts: Track the timing and outcomes of the PROPEL 3 (infigratinib), encaleret, and FORTIFY (BBP-418) trials scheduled for H2 2025.
- Bayer Milestone Receipt: Confirm the receipt of the $75.0 million regulatory milestone payment from Bayer in Q2 2025.